Rubius Therapeutics, Inc. (RUBY)
(Delayed Data from NSDQ)
$15.55 USD
-0.23 (-1.46%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[RUBY]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Considerations on Upcoming Milestones Across RUBY?s Pipeline; Reit Buy and Lowering Our PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
RTX-240 Data Produces Mixed Signals at AACR But There Is a Path Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
RUBY Ready To Walk The Red Carpet; Reit Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
From Antigen-Specific Immune Activation to Tolerance: RCTs Can Do It All
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Earlier-stage Assets Have Key Infection Points in 2022; Reit. Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
RTX-240 Continues its Assault on Solid Tumors; Reit Buy and $40PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Recent RTX-240 Data Giving the Green Light for the RED Platform; Reit Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
RTX-240 Initial Clinical Data Lessens Pipeline Risk; Reit Buy and Raising PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Strong Pipeline Execution Continues; Reit Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Our Thoughts on RTX-321 and Red Cell Therapeutics Platform
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Oncology Pipeline Continues to Advance; Reit Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Steady Progress With Oncology Pipeline; Reit Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Thoughts Following Pipeline Reprioritization; Reit Buy and Reducing PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Thoughts Following Delay of First-in-Human Data; Reit Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
First-in-Human Data to Be Readout by Year end as Planned; Reit Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Believe RTX-240?s Differentiated Value Propositions Are Underappreciated
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
|